Last day of trading including right to dividend shares in I-Tech AB

Today, Wednesday, August 15, is the last day Vicore Pharma Holding (publ) (ticker: VICO) share is traded including the right to dividend shares in I-Tech AB (publ)

On August 13, 2018, the EGM of Vicore Pharma Holding AB ("the Company") resolved that the record date for the distribution of shares in I-Tech AB will be August 17, 2018. This means that the last day of trading including the right to dividend is Wednesday, August 15, 2018. On Thursday, August 16, the share is traded exclusive of the right to dividend.

The dividend means that shareholders are entitled to receive one (1) share in I-Tech AB for every eight (8) shares in Vicore Pharma Holding AB (publ) held on the record date. The shareholders whose possession per the record day is not equally divisible with eight shall be entitled to a fraction of an I-Tech share as follows. Each surplus fraction shall entitle to an eighth of a share in I-Tech. All such fractions of shares in I-Tech shall be consolidated to whole shares which thereafter are to be sold by the Company on the market. The payment, without subtraction for brokerage, is to be paid to the relevant shareholders. The distribution is a distribution in kind that does not fall within the Lex Asea rule why the distribution is fully taxable. 

I-Tech was listed on Nasdaq First North on May 28, 2018. In conjunction with the listing, the Company, like other major owners of I-Tech, entered into a lock-up agreement meaning that the shares cannot be divested within a period of 12 months from the first day of listing. The distributed shares in I-Tech are included in the lock-up and will have a Euroclear deposit reservation, meaning that they will not be tradable until May 28, 2019. 

For further information contact

Per Jansson, CEO, 0709-17 47 46, per.jansson@vicorepharma.com

About Vicore Pharma Holding
Vicore Pharma AB develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and USA. In addition, C21 is explored pre-clinically for a number of diseases where the AT2 receptor plays an important role. I-Tech AB is an associated company to Vicore Pharma Holding. The company has developed and commercialized Selektope® , an effective chemical agent used as an antifouling ingredient in antifouling paints. The companies are based in AstraZeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, please refer to www.vicorepharma.com

Tags:

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com